{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T22:02:38Z","timestamp":1788732158406,"version":"build-2803163510"},"reference-count":31,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T00:00:00Z","timestamp":1762041600000},"content-version":"vor","delay-in-days":32,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["alz-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alz &amp; Dem Diag Ass &amp; Dis Mo"],"published-print":{"date-parts":[[2025,10]]},"abstract":"Abstract<\/jats:title>\n \n INTRODUCTION<\/jats:title>\n Alzheimer's disease (AD) diagnosis has been based largely on clinical symptoms, despite their limited sensitivity and specificity. Biomarker use was proposed to support a more accurate and timely diagnosis. However, neuroimaging or cerebrospinal fluid (CSF) is rarely used in primary care due to their perceived invasiveness, cost, and need for appropriate infrastructure. Blood\u2010based biomarkers (BBMs) could represent an economical, minimally invasive alternative, but barriers exist to a seamless translation to the clinic.<\/jats:p>\n <\/jats:sec>\n \n METHODS<\/jats:title>\n Ten international experienced AD clinicians and biomarker experts participated in a diagnostic roundtable to discuss the implementation of BBMs for diagnosing early symptomatic AD.<\/jats:p>\n <\/jats:sec>\n \n RESULTS<\/jats:title>\n The participants proposed an optimal AD diagnostic pathway and highlighted three main gaps to implementing BBMs for early symptomatic AD diagnosis: limited real\u2010world data, resource gaps, and system barriers.<\/jats:p>\n <\/jats:sec>\n \n DISCUSSION<\/jats:title>\n Although BBMs could streamline the AD diagnostic pathway, further real\u2010world evidence and collaboration among multiple stakeholders are needed.<\/jats:p>\n <\/jats:sec>\n \n Highlights<\/jats:title>\n \n \n \n Early symptomatic Alzheimer's disease (AD) diagnosis improves treatment strategy and lowers costs.<\/jats:p>\n <\/jats:list-item>\n \n Currently available biomarkers are not widely used across all clinical settings.<\/jats:p>\n <\/jats:list-item>\n \n Blood\u2010based biomarkers (BBMs) could be a cost\u2010effective, minimally invasive alternative.<\/jats:p>\n <\/jats:list-item>\n \n BBMs could accelerate an accurate AD diagnosis.<\/jats:p>\n <\/jats:list-item>\n \n There are barriers to the inclusion of BBMs in clinical practice.<\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1002\/dad2.70207","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T04:18:32Z","timestamp":1762143512000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["How can Alzheimer's disease blood\u2010based biomarkers reach clinical practice?"],"prefix":"10.1002","volume":"17","author":[{"given":"Robert","family":"Perneczky","sequence":"first","affiliation":[{"name":"Department of Psychiatry and Psychotherapy LMU Hospital LMU Munich Munich Germany"},{"name":"German Center for Neurodegenerative Diseases (DZNE) Munich Munich Germany"},{"name":"Munich Cluster for Systems Neurology (SyNergy) Munich Germany"},{"name":"School of Public Health Imperial College London London UK"},{"name":"Division of Neuroscience University of Sheffield, Western Bank Sheffield UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1467-6880","authenticated-orcid":false,"given":"Frances\u2010Catherine","family":"Quevenco","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Hendrix","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephane","family":"Epelbaum","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Teunissen","sequence":"additional","affiliation":[{"name":"Neurochemistry Lab Department of Laboratory Medicine Amsterdam Neuroscience Amsterdam University Medical Centers Vrije Universiteit Amsterdam Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiesje M.","family":"van der Flier","sequence":"additional","affiliation":[{"name":"Alzheimer Center Amsterdam Department of Neurology Amsterdam University Medical Centers Vrije Universiteit Amsterdam Amsterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Su\u00e1rez\u2010Calvet","sequence":"additional","affiliation":[{"name":"Barcelona\u03b2eta Brain Research Center Pasqual Maragall Foundation Barcelona Barcelona Spain"},{"name":"Servei de Neurologia Hospital del Mar Barcelona Spain"},{"name":"Hospital del Mar Research Institute Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiong","family":"Shi","sequence":"additional","affiliation":[{"name":"Department of Neurology The First Affiliated Hospital of University of Science and Technology Hefei Anhui China"},{"name":"Neurodegenerative Disorder Research Center Division of Life Sciences and Medicine University of Science and Technology of China Hefei Anhui China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle M.","family":"Mielke","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Prevention Wake Forest University School of Medicine Winston\u2010Salem North Carolina USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Iwatsubo","sequence":"additional","affiliation":[{"name":"The University of Tokyo Bunkyo Ward Tokyo Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Palmqvist","sequence":"additional","affiliation":[{"name":"Clinical Memory Research Unit Department of Clinical Sciences in Malm\u00f6 Lund University, Johannesgatan Malm\u00f6 Sweden"},{"name":"Memory Clinic Sk\u00e5ne University Hospital Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oskar","family":"Hansson","sequence":"additional","affiliation":[{"name":"Eli Lilly and Company Indianapolis Indiana USA"},{"name":"Clinical Memory Research Unit Department of Clinical Sciences in Malm\u00f6 Lund University, Johannesgatan Malm\u00f6 Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,2]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13809"},{"key":"e_1_2_9_3_1","volume-title":"Dementia","author":"WHO","year":"2025"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2023.115522"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(20)32205\u20104"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.13855"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010150692"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13859"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2024.3770"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41380\u2010024\u201002709\u2010z"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41582\u2010024\u201000977\u20105"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.13455"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2023.4596"},{"key":"e_1_2_9_14_1","volume-title":"Preferred Product Characteristics of Blood\u2010Based Biomarker Diagnostics for Alzheimer Disease","author":"WHO","year":"2024"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12756"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.14184"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.12081"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000201597"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41398\u2010023\u201002558\u20104"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12737"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12402"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001579\u20105"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13195\u2010024\u201001469\u2010w"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43587\u2010024\u201000731\u2010y"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjqs\u20102024\u2010017591"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.3934\/publichealth.2022047"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.3233\/JAD\u2010180196"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.70535"},{"key":"e_1_2_9_29_1","volume-title":"Nationale Demenzstrategie. The National Dementia Strategy","year":"2020"},{"key":"e_1_2_9_30_1","volume-title":"S3 Guideline Dementia\u2014Living Guideline","author":"Association of Scientific Medical Societies in Germany (AWMF)","year":"2025"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/alz.12578"},{"key":"e_1_2_9_32_1","volume-title":"Fujirebio Receives Marketing Clearance for Lumipulse\u00ae G p\u2010tau217\/\u03b2\u2010Amyloid 1\u201042 Plasma Ratio In\u2010Vitro Diagnostic Test as an Aid to Identify Patients with Amyloid Pathology Associated with Alzheimer's Disease","author":"FUJIREBIO","year":"2025"}],"container-title":["Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/dad2.70207","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T13:12:05Z","timestamp":1767013925000},"score":1,"resource":{"primary":{"URL":"https:\/\/alz-journals.onlinelibrary.wiley.com\/doi\/10.1002\/dad2.70207"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/dad2.70207"],"URL":"https:\/\/doi.org\/10.1002\/dad2.70207","archive":["Portico"],"relation":{},"ISSN":["2352-8729","2352-8729"],"issn-type":[{"value":"2352-8729","type":"print"},{"value":"2352-8729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"2025-05-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-01","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70207"}}